Agenus surges on $85 million financing and Phase 3 colon cancer strategy shift

By: Quiver PriceTracker

Posted: 6 hours ago / July 13, 2026 2:49 p.m. UTC

AGEN

Agenus Inc. (AGEN) is up 130.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The biggest apparent catalyst is a newly announced private placement that brings in about $85 million upfront and potentially much more if warrants are exercised. Investors also appear to be reacting to Agenus concentrating resources on an FDA-aligned Phase 3 program for BOT+BAL in microsatellite-stable colon cancer, which gives the company a clearer funding path and development focus.

Details:

Agenus disclosed a private placement expected to deliver about $85 million in gross proceeds upfront, with additional proceeds possible from warrant exercises.

The company said the cash, together with existing resources, should fund operations into the third quarter of 2027 even without warrant exercise, and potentially much longer if all warrants are exercised.

Management said the financing is intended to support ROBBIN, a planned 850-patient global Phase 3 trial of botensilimab plus balstilimab in previously untreated high-risk Stage II and Stage III MSS colon cancer.

Agenus also said it plans to discontinue financial support for the BATTMAN metastatic colorectal cancer study, signaling a sharper strategic pivot toward the neoadjuvant colon cancer opportunity.

Sources:

SEC, Agenus, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive AGEN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$AGEN Hedge Fund Activity

We have seen 23 institutional investors add shares of $AGEN stock to their portfolio, and 48 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MARSHALL WACE, LLP added 541,403 shares (+368.8%) to their portfolio in Q1 2026, for an estimated $1,808,286
ACADIAN ASSET MANAGEMENT LLC removed 407,437 shares (-65.5%) from their portfolio in Q1 2026, for an estimated $1,360,839
CITADEL ADVISORS LLC removed 371,238 shares (-87.7%) from their portfolio in Q1 2026, for an estimated $1,239,934
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 277,912 shares (-99.8%) from their portfolio in Q1 2026, for an estimated $928,226
RENAISSANCE TECHNOLOGIES LLC removed 257,900 shares (-47.4%) from their portfolio in Q1 2026, for an estimated $861,386
MILLENNIUM MANAGEMENT LLC removed 181,930 shares (-80.7%) from their portfolio in Q1 2026, for an estimated $607,646
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 176,015 shares (-75.3%) from their portfolio in Q1 2026, for an estimated $587,890

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.